About US
Contact us
-
Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge fNovartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna® US General Medicines restructurin2012/1/16
-
Foreign firms reap 60% of China's healthcare stimulusExperts on China have a cautionary bit of advice for drugmakers: The devil is in the details. On a top-line basis, China's pledge of a $125 billion investment in healthcare this year looks great. In2012/1/13
-
Pharma faces China healthcare challengePharma faces China healthcare challengeBy Benjamin A Shobert SAN FRANCISCO - Milling around the hotel lobby at the Sir Francis Drake hotel in downtown San Francisco are an ecle2012/1/13
-
Drug Reps Soften Their Sales PitchesBy JONATHAN D. ROCKOFF GREENSBORO, N.C.—One thing was noticeably absent from a recent visit that an Eli Lilly & Co. sales representative paid to a psychiatrist here: a sales pitch. Michaelene G2012/1/12
-
Glaxo Is Keen to Advance Rest of OTC Asset Sale, CFO SaysGlaxoSmithKline Plc (GSK) is trying to sell its remaining over-the-counter medicine brands as quickly as possible, Chief Financial Officer Simon Dingemans said. Prestige Brands Holdings Inc. (PBH),2012/1/12
-
FDA: Endo opioids may be mixed in Novartis OTC packagesThe FDA has added its two cents to the Novartis ($NVS)consumer-drug recall. The agency has issued an advisory to healthcare professionals and patients that says some Endo Pharmaceuticals ($ENDP)pain2012/1/12
-
Novartis plant's quality control understaffed, inadequately trained, FDA saysNovartis ($NVS) temporarily pulled the curtains on its Lincoln, NE, consumer drug plant in late December. What's been going on behind those windows? Pharmalot reports that, after a recent visit, FDA2012/1/11
-
Novartis pulls OTC meds made at troubled plantOn the heels of a temporary plant shutdown last month, Novartis ($NVS) has recalled four over-the-counter drugs made there. It's a precautionary recall, the company's consumer health division report2012/1/11
-
European Pharma Industry Seen ‘Rising From the Ashes’ in Mid-2012By Sten Stovall Investment prospects for Europe’s big drug makers look set to improve dramatically from mid-2012, despite the gloomy backdrop facing the sector as the year begins. In 2012, th2012/1/10
-
Pfizer’s Lipitor Market Share to Fall More, Watson CEO SaysPfizer Inc. (PFE)’s market share for the cholesterol pill Lipitor (PHAM1150), now at 41 percent after losing patent protection last year, will decline further in the next five months, according to gen2012/1/10